JP2019147777A - Myokine production promoting composition - Google Patents

Abstract

To provide a composition having a myokine production promoting action.SOLUTION: A myokine production promoting composition contains plant-derived essential oil and/or menthol.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a composition for promoting myokine production in a living body.

Skeletal muscle is a motor organ that represents 40% of body weight. Recent research has revealed that it is not only involved in exercise, but also has the role as the largest hormone-secreting organ in the human body. The humoral factors secreted from muscle are collectively called Myokine. Myokine acts on autocrine, paracrine, and endcrine, and affects the physiological functions of other organs such as blood vessels, fat, skin, liver, kidneys, bones, brain, digestive organs, immune system organs as well as muscles themselves. (Non-patent Document 1).
From secretome analysis of cultured human skeletal muscle, 300 or more humoral proteins are listed as myokine candidate substances (Non-patent Document 2). The most representative of myokines is interleukin-6 (IL-6), which is considered to be responsible for crosstalk between muscles and various other organs (see Non-Patent Document 1). Various actions such as action, antidiabetic action (Non-patent Document 3), anti-obesity action (Non-Patent Document 4) have been reported. Changes in the amount of myokine produced in muscle can be confirmed using IL-6 as an index.

  As other myokines, angiopoietin-like protein 4 (Angptl4) has an anti-obesity action, interleukin-15 (IL-15) has an anti-obesity action and skin anti-aging action, thioredoxin-1 has an antioxidant action, and secreted protein. Acidic and Rich in Cystein (SPARC) has been reported to have an anticancer effect. Brain-derived neurotrophic factor (BDNF) is thought to act on the brain and participate in memory / learning and emotional regulation. Thus, many of myokines contribute to health promotion. However, generally the muscle mass of the whole body decreases with aging. For this reason, the total amount of myokine also decreases with age.

In modern society, it is important to extend the healthy life expectancy. For this reason, it is a very useful method to maintain and promote the secretion of myokine and utilize its health promoting effect.
Moreover, many myokines are secreted constantly, and it is known that the amount of secretion may be fluctuate | varied by stimulation, such as muscle contraction, mechanical stimulation, and insulin (nonpatent literature 5). For example, many myokines have been reported to increase in blood concentration due to exercise such as IL-6 and IL-15 (Non-patent Document 6). Some of the health and beauty enhancement effects of exercise are thought to be due to myokines. In recent years, however, women's exercise habits have decreased, and it has become clear that men and women in their 30s have the least exercise habits, and myocin secretion can be easily performed not only by the elderly but also by young people. There is a need for methods to promote both health and beauty.
However, there has not yet been provided a specific method or composition for promoting the promotion of mica ion production without muscle exercise.

Pedersen BK, Febbraio MA. Nat Rev Endocrinol. 2012 Apr 3; 8 (8): 457-65. Hartwig S et al., Biochim Biophys Acta. 2014 May; 1844 (5): 1011-7. Karstoft K, Pedersen BK. Curr Opin Clin Nutr Metab Care. 2016 Jul; 19 (4): 270-5. Carey AL et al., Diabetes. 2006 Oct; 55 (10): 2688-97. Manabe Y et al., J Phys Fitness Sports Med. 2012; 1 (1): 51-58. Drenth JP et al., J Appl Physiol (1985). 1995 Nov; 79 (5): 1497-503.

The present inventor has a strong myokine secretion promoting effect in a composition containing plant-derived essential oil, menthol, linalyl acetate, linalool, α-pinene, and limonene in the course of studying a method for promoting myokine secretion independent of muscle exercise. I found out that I made the present invention.
That is, an object of the present invention is to provide a composition having a myokine production promoting action.

The main configuration of the present invention is as follows.
(1) A composition for promoting myokine production containing plant-derived essential oil and / or menthol as an active ingredient.
(2) The composition for promoting myokine production according to (1), wherein the plant-derived essential oil is an essential oil containing one or more substances selected from linalyl acetate, linalool, α-pinene, and limonene.
(3) The myokine production promotion according to (1) or (2), wherein the plant-derived essential oil comprises one or more plant-derived essential oils selected from chamomile, rosemary, sardine, mint, lavender and orange. Composition.
(4) The composition for promoting myokine production according to any one of (1) to (3), which is an external preparation.
(5) A composition for promoting myokine production containing 0.001 to 50% by mass of plant-derived essential oil and / or 0.001 to 1% by mass of menthol.

The composition of the present invention has an action of promoting muscle myokine production. It also recovers or improves the decrease in myokine production ability due to lack of exercise and poor blood circulation, and enhances myokine production.
Myokine produced by muscle tissue regulates the physiological functions of not only muscle itself but also adipose tissue, pancreas, immune system tissue, cranial nerve, bone, etc. through blood flow, anti-muscular atrophy, anti-obesity, anti-diabetes It has effects such as anti-inflammatory, memory promotion, nerve regeneration, bone regeneration, and anticancer. In particular, in the fibroblast tissue constituting the skin tissue, the fibroblast is proliferated, and the amount of collagen produced by the fibroblast is increased.

It is a graph which shows that 0.01 mass% addition of the composition of this invention accelerates | stimulates myokine production. It is a graph which shows that 0.05 mass% addition of the composition of this invention accelerates | stimulates myokine production. It is a graph which shows that 0.3 mM or 0.03 mM addition of the composition of this invention accelerates | stimulates myokine production. It is a graph which shows that chamomile essential oil promotes myokine production. It is a graph which shows that lactic acid suppresses myokine production in the myotube tissue of the differentiation 3rd day. It is a graph which shows that lactic acid suppresses myokine production in the myotube tissue of the differentiation 7th day. It is a graph which shows that the composition of this invention recovers myokine production suppression of the myotube tissue by lactic acid. It is a graph which shows that the culture solution containing the myokine which a myotube tissue produces promotes the proliferation of a fibroblast. It is a graph which shows that the culture solution containing the myokine which myotube tissue produces reduces the mitochondrial membrane potential of a fibroblast. It is a graph which shows that the culture solution containing the myokine which myotube tissue produces contracts the collagen gel containing a fibroblast.

The present invention relates to a composition for promoting myokine production containing plant-derived essential oil and / or menthol.
The composition of the present invention will be described.
In the composition of the present invention, the component showing the action of promoting muscle myokine production is plant-derived essential oil and / or menthol. A composition containing one or more essential oils or menthols exhibiting myokine production promoting action can be used as a composition for promoting myokine production.
Examples of essential oils that promote the production of myokine include those containing linalyl acetate and / or linalool and / or α-pinene and / or limonene as ingredients, and are obtained from chamomile, rosemary, mulberry, mint, lavender and orange. The essential oil is representative.

  Chamomile (scientific name: Matricaria recutita) is a kind of cold-tolerant annuals of the family Asteraceae, and the Japanese name is chamomile. Two types of chamomile, Roman chamomile and German chamomile, are generally known, but any type of chamomile may be used in the present invention. Chamomile oil extracted from chamomile flowers by steam distillation can be used in the present invention. Commercially available essential oils can be used in the present invention. As the essential oil component, Roman chamomile is angelic acid isobutyl, angelic acid isoamyl, angelic acid methyl, isobutyric acid isoamyl, angelic acid 2-methylbutyrate, German chamomile is bisabolol oxide A, camazulene, cis-t-dicyclo. Ether, bisabolol oxide B, bisabolen oxide and the like are included.

  Rosemary (Rosmarinus officinalis L) is an evergreen shrub that belongs to the Labiatae family and is also called the Japanese name Mannenrou. Essential oil extracted from whole plant by steam distillation is used in the present invention. Commercially available rosemary essential oil can be used in the present invention. The essential oil component includes α-pinene, 1,8-cineole, camphor, camphene, limonene and the like.

  Nyukoju (Nakkou Tree, scientific name: Boswellia carterii Birdw.) Is a shrub that grows naturally in the tropical dry zone, and the resin collected from the trunk is called frankincense or pills. In the present invention, an essential oil obtained by steam-distilling milk perfume is used as a “Nyukoju essential oil” in a composition for promoting myokine production. Commercially available Nyukouju essential oil can be used in the present invention. The essential oil component includes α-pinene, α-twen, p-cymene, limonene, sabinene and the like.

  In the present invention, mint refers to Japanese mint (scientific name: Mentha canadensis var. Piperascens), but in the present invention, so-called "mint" plants such as spearmint classified as genus mint including Japanese mint, It ’s called “mint”. The essential oil derived from mint of the present invention can be used in the present invention as long as it is an essential oil (mint oil) obtained by steam distillation of the whole plant of these mint species. Examples of such mint include Japanese mint, Atlantic mint, spearmint, peppermint, bergamot, and apple mint. In this invention, what was marketed as a foodstuff or cosmetic raw material or a fragrance | flavor can be used.

  Lavender (scientific name: Lavendula angustifolia P. Miller) is a perennial plant belonging to the family Lamiaceae that is cultivated at an altitude of 800-1000m. In the present invention, the essential oil obtained by steam distillation of lavender is used as "lavender essential oil". To do. Commercially available lavender essential oil can be used in the present invention. The essential oil component includes linalyl acetate, linalool, cis-β-oximene, terpinen-4-ol, and the like.

  Oranges are roughly classified into sweet oranges (scientific name: Citrus sinensis L. Osbeck), bitter oranges (scientific name: Citrus aurantinum L.), and mandarin oranges (scientific name: Citrus reticulata). The essential oil obtained by squeezing orange peel is used as “orange essential oil”. Commercially available orange essential oil can be used in the present invention. As essential oil components, sweet orange includes limonene and n-octanal, bitter orange includes limonene and myrcene, mandarin orange includes limonene, γ-terpinene, α-pinene, myrcene, β-pinene and the like.

Menthol is a cyclic monoterpene, a kind of organic compound of alcohol, and the system name of the IUPAC nomenclature is 2-isopropyl-5-methylcyclohexanol (CAS registration number: 2216-51-5). It is a volatile colorless crystal with a so-called mint smell. Although menthol has several diastereomers and enantiomers, the present invention may be these isomers or a mixture thereof. Among them, l-menthol is a compound used for pharmaceuticals because it has many local vasodilatory effects, skin irritation effects and the like, as well as confectionery such as toothpaste and chewing gum, and fresheners in the mouth.
In the present invention, purified menthol isolated from the mint essential oil or a chemically synthesized product obtained by an asymmetric synthesis method can be used.
The composition of this invention can be used as a foodstuff, a pharmaceutical, and an external preparation. As a food, it may be used as a dietary supplement, a functional food, a health food, a food for specified health use or the like in addition to a normal food, and can be blended in a beverage such as a juice.

  In pharmaceutical use, for administration, the active ingredient is mixed with a solid or liquid non-toxic pharmaceutical carrier suitable for administration methods such as oral administration, parenteral ingestion, rectal administration, injection, etc. Can be administered. Examples of the form include solid agents such as powders, powders, granules, tablets and capsules, solutions such as solutions, suspensions and emulsions, freeze-dried preparations, and external preparations. These preparations can be prepared by conventional means. Examples of the pharmaceutical carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethylene starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, albumin, Water, physiological saline, etc. are mentioned. If necessary, additives such as stabilizers, wetting agents, emulsifiers, binders, tonicity agents and the like can be added as appropriate.

  The dosage of the composition of the present invention is appropriately selected and determined according to the age, weight, symptom, administration route, administration schedule, formulation form, etc. of the subject. In the case of oral administration, 1 to 240 mg per day is preferable. A composition containing 0.001 to 50% by mass of essential oil and 0.001 to 1% by mass of menthol is administered a plurality of times per day.

  Moreover, the composition of this invention is used for an emulsion, cream, lotion, ointment, etc. as an external preparation. Although not particularly limited, the dosage form is an aqueous solution system, a solubilization system, an emulsification system, a powder system, an oil liquid system, a gel system, an ointment system, an aerosol system, a water-oil two-layer system, a water-oil- A dosage form such as a powder three-layer system can be used.

Hereinafter, the present invention will be specifically described with reference to test examples.
Test 1. Myocine production promoting action confirmation test for muscle (1) Test method Myotube tissue formed by cultured striated muscle cells was used as a muscle tissue model.
1) Myotube formation Myotubes were formed using cultured mouse striated myocyte C2C12 strain (DS Pharma Biomedical Co., Ltd.). The growth medium used was a DMEM high glucose (GIBCO) containing 10% FBS and 1% penicillin / streptomycin (Sigma Aldrich /). A T75 flask was used for passage of C2C12 cells, and seeded so that the number of cells per flask was 1.5 × 10 ⁵ cells.
It was confirmed by microscopic observation that the cell density was 60 to 70% of the flask area in 2 to 3 days after the passage, and the cells were detached using 0.05% Trypsin-EDTA. Subsequently, the cells were seeded on a 6-well plate coated with 0.02% collagen (Koken Co., Ltd.) so that the number of cells per well was 1.8 × 10 ⁴ cells.
Subsequently, after confirming that the cells reached confluence, the growth medium was switched to the differentiation medium.
As a differentiation medium, a medium containing 2% Horse serum in DMEM high glucose (GIBCO) and 1% non-essential amino acid solution (NEAA: Sigma Aldrich) and 1% penicillin / streptomycin was used. Three to seven days after the medium switching, it was confirmed with a microscope that myotubes were sufficiently formed. Those in which myotube tissue was formed were used in the following tests.
All cell culture environments were 37 ° C. and 5% CO ₂ .

2) Myokine production promotion test (IL-6)
The myokine production promoting effect was tested using the myotube tissue of the 3rd day of differentiation prepared above.
The essential oil used in the test is a commercially available essential oil for perfumery, which is rosemary essential oil (RM rosemary oil, Kaoe Kogyo), chamomile essential oil (RM Roman chamomile oil, PATAN & BERTRAND), New York oil, Yamamoto fragrance), and menthol (L-menthol, Wako Pure Chemical Industries) and linalyl acetate (Wako Pure Chemical Industries), linalool (Wako Pure Chemical Industries), α-pinene (Wako Pure Chemical Industries), limonene ( Wako Pure Chemical Industries) was used. As a positive control, a synthetic peptide, MG-132 (Z-Leu-Leu-Leu-CHO: American Peptide), which is apparent to promote myokine production in muscle tissue, was used. These added components were uniformly dispersed by an ultrasonic crusher after being added to the differentiation medium.
Each essential oil and menthol was added so that the concentration in the medium was 0.01% by mass and 0.05% by mass, linalyl acetate, α-pinene, limonene was 0.3 mM, and linalool was 0.03 mM. After culturing, the medium was replaced with a new differentiation medium, and after culturing for 5 hours, the supernatant of the medium was collected and the change in myokine was measured. The amount of IL-6 was measured as an index of myokine. IL-6 was measured using mouse / rat soluble protein Master Buffer Kit (Nippon Becton Dickinson) and mouse soluble protein Flex set IL-6 (Nippon Becton Dickinson) using FACS Calibur (Nippon Becton Dickinson). The amount of IL-6 protein contained in the prepared medium supernatant was measured.

3) Myokine production promotion test (Angplt4)
Using the myotube tissue on the third day of differentiation prepared above, the production promoting effect of Angptl4, one of the myokines involved in lipid metabolism, was tested at the gene expression level.
The essential oil used in the test was a commercially available aromatic chamomile oil, which was added to the differentiation medium and then uniformly dispersed by an ultrasonic crusher.
Essential oil was added so that the density | concentration in a culture medium might be 0.01 mass% and 0.1 mass%, and after culture | cultivating for 1 hour, it replaced | exchanged for the new differentiation culture medium, and extracted RNA from the cell after the culture | cultivation for 3 hours. For the reverse transcription from RNA to cDNA, PrimeScript RT reagent Kit (Takara Bio) and TaKaRa PCR Thermal Cycler Dice (registered trademark) GradientTP600 (Takara Bio) were used. SYBR (registered trademark) Premix Ex Taq (trademark) II (Tli RNaseH Plus) (Takara Bio) and LightCycler 480 system II (Roche Diagnostics) were used for the quantitative PCR reaction. Β-glucosidase (Gusb) was used as a housekeeping gene. Table 1 shows the sequences of the primers for Gusb and Angptl4 based on the mouse sequence (sequences 1 to 4).

(2) Test result The result of having measured the IL-6 production-promoting effect by each essential oil and menthol was shown in FIG. 1 (0.01 mass%) and FIG. 2 (0.05 mass%). In addition, the measurement result was shown by the relative value which set the production amount of the control (control) to 1.
From FIGS. 1 and 2, it was confirmed that rosemary essential oil, chamomile essential oil, scented essential oil, and menthol all promote the production of IL-6. In addition, it was confirmed that the synthetic peptide MG-132 that clearly promotes myokine production also promoted IL-6 production every trial.
FIG. 3 shows the results of measuring the IL-6 production promoting effect by linalyl acetate, linalool, α-pinene and limonene. The measurement results are shown as relative values with the expression level of the control being 1.
As is clear from FIG. 3, it was confirmed that linalyl acetate, linalool, α-pinene, and limonene all promote the production of IL-6.
FIG. 4 shows the results of measuring the effect of promoting the expression of Angptl4 gene by chamomile essential oil. The measurement results are shown as relative values with the expression level of the control being 1.
From FIG. 4, it was confirmed that chamomile essential oil promotes not only the production of IL-6 but also the expression of the Angptl4 gene.

Test 2. Myocine production ability suppression confirmation test by lactic acid accumulation The suppression of myokine production ability of muscle by lactic acid accumulation was confirmed. The test will be described next.
(1) Test method As in Test 1, myotube tissue formed by cultured striated muscle cells was used as a muscle tissue model.
1) Myotube formation Myotubes were formed in the same manner as in Test 1. This was used for testing.

2) Confirmation test of myokine production suppression by lactic acid load The test was performed using the myotube tissue of the 3rd day of differentiation prepared above.

3) Lactic acid load After 3 days and 7 days after differentiation induction, myotubes were cultured for 24 hours in a medium containing 0 to 40 mM lactic acid, and the culture supernatant was collected, and IL-6 in the medium was recovered in the same manner as in Test 1. It was measured.

(2) Test results Fig. 5 (differentiation day 3) and Fig. 6 (differentiation day 7) show the measurement results of IL-6 produced by myotubes.
As is apparent from FIGS. 5 and 6, it was confirmed that lactic acid suppressed the myokine production function of muscle.

Test 3. Inhibition test of myokine production ability by lactic acid accumulation The suppression of myokine production ability of muscle by lactic acid accumulation was confirmed. The test will be described next.
(1) Test method As in Test 1, myotube tissue formed by cultured striated muscle cells was used as a muscle tissue model.
1) Myotube formation Myotubes were formed in the same manner as in Test 1. This was used for testing.

2) Recovery test from suppression of myokine production by lactic acid load The test was performed using the myotube tissue of differentiation 3rd day prepared above.

3) Lactic acid load Three days after induction of differentiation, myotubes were cultured for 1 hour in a medium containing 20 mM lactic acid, or cultured for 1 hour in a medium to which 20 mM lactic acid and each essential oil or menthol 0.01% by mass were added, and then a new differentiation medium The culture supernatant was recovered after 5 hours of culturing, and IL-6 in the medium was measured in the same manner as in Test 1.

(2) Test results Fig. 7 shows the measurement results of IL-6 produced by myotubes. The measurement results are shown as relative values with the production amount of the control (without addition of lactic acid, essential oil or menthol) being 1.
As is clear from FIG. 7, lactic acid suppresses muscle myokine production function, but adding essential oil or menthol eliminates the myokine production inhibitory effect of lactic acid and promotes myokine production. It was. Moreover, it became clear that the functional decline accompanying lactic acid accumulation can be prevented.

  From the results of Test 1, Test 2 and Test 3, plant-derived essential oil or menthol acts on muscle tissue to promote myokine production, and further eliminates the effects of lactic acid accumulation associated with lack of exercise and poor circulation. It can be said that it has.

Test 4. Test of effect of myokine on fibroblasts The effect on fibroblasts existing in the vicinity of muscle tissue was confirmed.
(1) Test method 1) Cell culture BALB / 3T3cell (passage 22 times) was used as fibroblasts. This was seeded at a cell density of 1 × 10 ⁴ cells / cm ² in one T25 culture flask and cultured for 3 days. Next, the cells were detached and collected with 0.025% trypsin-EDTA, and further seeded at 5 × 96 well plates at 1 × 10 ⁴ cells / ml.
The medium was exchanged while growing to 80% of confluence.
As the replacement medium, the medium on the 7th day cultured using the medium for differentiation of C2C12 cells shown in Test 1 was collected and mixed with the medium of 3T3 cells at the mixing ratio shown in Table 2.
After 24 hours of medium change, the number of cells was measured using Cell Counting Kit-8 (Dojindo Laboratories).

2) Measurement of mitochondrial activity of fibroblasts (3T3) BALB / 3T3 cells (passage 22 times) were used as fibroblasts. This was seeded at a cell density of 1 × 10 ⁴ cells / cm ² in one T25 culture flask and cultured for 3 days. Subsequently, the cells were detached and collected with 0.025% trypsin-EDTA, and further seeded at 2 x T75 flasks at 0.8 × 10 ⁴ cells / ml.
The medium was exchanged while growing to 80% of confluence.
As the replacement medium, the medium on the 7th day cultured using the medium for differentiation of C2C12 cells shown in Test 1 was collected and mixed with the medium of 3T3 cells at the mixing ratio shown in Table 2.
Mitochondrial membrane potential was measured by MitoProbe ™ JC-1 assay (Molecular probes) 24 hours after medium change.

3) Collagen gel contraction measurement of fibroblast (3T3) BALB / 3T3 cell (passage 22 times) was used as fibroblast. This was seeded at a cell density of 1 × 10 ⁴ cells / cm ² in one T25 culture flask and cultured for 3 days. Subsequently, the cells were detached and collected with 0.025% trypsin-EDTA, and further seeded at 2 x T75 flasks at 0.8 × 10 ⁴ cells / ml.
The medium was exchanged while growing to 80% of confluence.
Six days after the medium exchange, the cells were detached and collected, and seeded on a collagen gel having the composition shown in Table 3. As the culture medium, the culture medium (Sup) on the 7th day cultured using the differentiation medium for C2C12 cells shown in Test 1 was collected, and mixed at the blending ratios shown in Table 4 were added.
After culturing for 7 days, the shrinkage of the collagen gel was observed and photographed, and the size of the obtained image was measured using Image-J to calculate the shrinkage rate.
Preparation of collagen gel and measurement of shrinkage were in accordance with the method described in JP-A No. 2011-157281.

(2) Results 1) Number of cells FIG. 8 shows the measurement results.
The number of fibroblasts increased corresponding to the amount of differentiation medium (Sup) added to C2C12 cells on day 7. It was considered that myokine secreted from myotube tissue contributed to the proliferation of fibroblasts.

2) Mitochondrial membrane potential FIG. 9 shows the measurement results of JC1. It was confirmed that the mitochondrial membrane potential of fibroblasts (3T3) decreased depending on the concentration of myotube culture supernatant (Sup).

3) Collagen gel contraction FIG. 10 shows the contraction rate obtained as a result of observing the contraction state of the collagen gel.
It was observed that the collagen gel containing fibroblasts (3T3) contracted depending on the concentration of myotube culture supernatant (Sup).
From the above test results, the following became clear.
The myotube culture supernatant caused the proliferation of fibroblasts (3T3), and a decrease in mitochondrial membrane potential was observed. This was thought to be because fibroblast activation was caused by myokine contained in the myotube culture supernatant, the cells proliferated, and the proliferation caused the decrease in mitochondrial membrane potential.
In the collagen gel contraction method, when fibroblasts are embedded in type I collagen gel and cultured under normal culture conditions, a phenomenon in which the volume of the collagen gel contracts is observed. It is known that the degree of collagen gel contraction increases as the number of cells increases or as the serum concentration in the medium increases. In addition, it has been clarified that the fibroblasts derived from the elderly have a lower ability to contract the gel than the fibroblasts derived from the young, and measurement of the contractility of the dermal fibroblast-embedded collagen gel Is used as a method for evaluating the elasticity and firmness of the dermis with age, and a drug for preventing and improving sagging. The fact that collagen gel contraction was observed in the myotube culture supernatant was considered that myokine contained in the myotube culture supernatant had an anti-aging effect on skin functions such as sagging.
From the above, plant-derived essential oil or menthol promotes myokine production, and the produced myokine acts on skin cell activation (proliferation), thereby contracting the collagen gel and improving skin sagging and wrinkles It was considered a thing.

The main configuration of the present invention is as follows.
(1) IL- which is one of myokines containing, as an active ingredient, one or more substances selected from chamomile essential oil, rosemary essential oil, nucurid essential oil, menthol, linalyl acetate, linalool, α-pinene and limonene production promoter of 6.
(2) An agent for promoting the production of Angptl4, which is one of myokines, containing chamomile essential oil as an active ingredient.
(3) An agent for suppressing a decrease in the ability to produce IL-6, which is one of myokines by lactic acid, containing, as an active ingredient, one or more substances selected from chamomile essential oil, rosemary essential oil, nucurous essential oil, and menthol.

The main configuration of the present invention is as follows.
(1) IL- which is one of myokines containing, as an active ingredient, one or more substances selected from chamomile essential oil, rosemary essential oil, nucurid essential oil, menthol, linalyl acetate, linalool, α-pinene and limonene 6 production promoters (excluding anti-diabetic agents and anti-obesity agents) .
(2) An agent for promoting production of Angptl4, which is one of myokines, containing chamomile essential oil as an active ingredient (excluding antidiabetic agents and antiobesity agents) .
(3) Chamomile essential oil, rosemary essential oil, Nyuukouju essential oil, containing one or more materials selected from menthol as an active ingredient, which is one IL-6 production ability of lowering inhibitor Maiokain by lactic acid (anti Except for diabetics and anti-obesity agents) .

Claims (5)

  A composition for promoting myokine production, comprising plant-derived essential oil and / or menthol as an active ingredient.   The composition for promoting myokine production according to claim 1, wherein the plant-derived essential oil is an essential oil containing one or more substances selected from linalyl acetate, linalool, α-pinene, and limonene.   The composition for promoting myokine production according to claim 1 or 2, wherein the plant-derived essential oil comprises one or more plant-derived essential oils selected from chamomile, rosemary, white mulberry, mint, lavender and orange.   The composition for promoting myokine production according to any one of claims 1 to 3, which is an external preparation.   A composition for promoting myokine production containing 0.001 to 50% by mass of plant-derived essential oil and / or 0.001 to 1% by mass of menthol.

Images